Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Covid-19 Seroprevalence - Do the Results Advance the Aims?

Version 1 : Received: 25 August 2020 / Approved: 27 August 2020 / Online: 27 August 2020 (12:47:12 CEST)

How to cite: Almogy, G. Covid-19 Seroprevalence - Do the Results Advance the Aims?. Preprints 2020, 2020080622 (doi: 10.20944/preprints202008.0622.v1). Almogy, G. Covid-19 Seroprevalence - Do the Results Advance the Aims?. Preprints 2020, 2020080622 (doi: 10.20944/preprints202008.0622.v1).

Abstract

Seroprevalence studies suggest that the number of PCR-confirmed COVID-19 cases is significantly smaller than the true number of infections. I study logintidual seroprevalence data from 7 sites across the US, from early April 2020 to June 27. I show that not only COVID-19 seroprevalence does not seem to increase over time, there is no clear association between the number of cases reported during a period and the change in seroprevalence during the same time. I conclude that as they are, seroprevalence studies can only be used in the qualitative sense and distinguish between populations with no COVID-19 exposure, to those populations where the virus had already started spreading.

Subject Areas

Serology; Seroprevalence; Humoral response; COVID-19; serosurvey; epidemiology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.